Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Touts Oral Triplet Regimen With Velcade Follow-On MLN9708

This article was originally published in PharmAsia News

Executive Summary

Results from the FIRST study of long-term treatment with Celgene’s Revlimid/dexamethasone duo were well-received at the ASH meeting. Takeda believes adding on its oral proteasome inhibitor MLN9708 to form a trio could further improve outcomes and is actively evaluating a role for maintenance in pivotal trials, following encouraging Phase I/II results.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts